IP Library Granted Patent US 9,169,464
Granted Patent B2
US 9,169,464 · App. 13/502,174 · Granted Oct 27, 2015

Closed system separation of adherent bone marrow stem cells for regenerative medicine applications

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,169,464
App. No.
13/502,174
Granted
Oct 27, 2015
Kind
B2
Abstract

A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described.

Claims (19)

1. A stem cell isolation kit comprising:

a) a first bag containing a plasma blood expander;

b) a second bag containing an anticoagulant and a growth medium, said second bag comprising an injection port for introduction of a biological sample comprising red blood cells and stem cells;

c) a third bag for collection of sedimented red blood cells from the second bag;

d) a fourth bag comprising an interior surface coated with a cell-adherent surface layer for collection and isolation of adherent stem cells;

e) a fifth bag containing a preservative for storage of adherent stem cells;

wherein said first and second bags are interconnected with each other through sterile tubing for transferring the contents of the first bag to the second bag; the second and third bags are interconnected with each other through sterile tubing for sedimenting red blood cells from the second bag to the third bag; the second and fourth bags are interconnected with each other through sterile tubing for transferring of stem cells from the second bag to the fourth bag; and wherein the fourth and fifth bags are interconnected with each other through sterile tubing for the transfer of adherent stem cells from the fourth to the fifth bag.

2. The kit of claim 1 , wherein said growth medium is selected from the group consisting of X-vivo, RPMI-1640, DMEM, and αMEM, or a combination thereof.

3. The kit of claim 2 , wherein said growth is RPMI-1640 or X-vivo medium.

4. The kit of claim 1 , further comprising a container of cell detachment solution connected to said fourth bag through sterile tubing.

5. The kit of claim 1 , further comprising aspirating means for collecting bone marrow aspirates.

6. The kit of claim 1 , wherein said interior surface of said fourth bag is corona discharge treated before being coated with said cell-adherent surface layer.

7. The kit of claim 1 , wherein said cell-adherent surface layer comprises a cell-adherent biopolymer, polypeptide, protein or polysaccharide.

8. The kit of claim 7 , wherein said cell-adherent surface layer comprises a coating of one or more basement membrane proteins.

9. The kit of claim 8 , wherein said basement membrane proteins are selected from the group consisting of fibronectin, collagen, laminin, keratin, fibrin and fibrinogen.

10. The kit of claim 7 , wherein said cell-adherent surface layer comprises a coating of one or more polysaccharides selected from the group consisting of hyaluronic acid, heparin sulfate, chondroitin sulfate and agarose.

11. The kit of claim 7 , wherein said cell-adherent surface layer comprises poly-L-lysine.

12. The kit of claim 1 , wherein said plasma blood expander in said first bag is hydroxyethyl starch (HES) and said anticoagulant in said second bag is selected from the group consisting of ACD, CPD, CPDA, heparin and sodium citrate.

13. The kit of claim 12 , wherein said first bag is graded to allow fixed ratio mixing of hydroxyethyl starch (HES) to an anti-coagulated bone marrow or biological fluid sample in said second bag to reach a final HES concentration of 1.2%.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Sep 5, 2013
From: THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 031170/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2012
From: SABAAWY, HATEM
To: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Reel/Frame 028223/0406 →